爱德华、美敦力慌了!集采强压背后,心脏瓣膜即将迎来降价潮

MedTrend医趋势
05 Jun

心脏瓣膜市场,这场技术追赶战,国产起步就晚了近十年。当爱德华TAVR产品在2007年拿下CE认证,中国首个TAVR产品于2017年才上市。当下,随着波士顿科学ACURATEneo2的退市,中国心脏瓣膜TAVR形成“2+10”格局。国产手握14款TAVR产品,在不足15%的夹缝中艰难求存。前有垄断,尽管医保放量,难掩国产头部企业启明、沛嘉、心通连年亏损超数十亿的残酷现实。而更大的风暴已至——集采大刀...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10